Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

Access Programs

Disease Information

Descriptive Information
Brief Title † Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
Official Title † Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults
Brief Summary The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.
Detailed Description
Study Phase Phase 1
Study Type † Interventional
Study Design † Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary Outcome Measure † Number of subjects with serious and non serious adverse events
Secondary Outcome Measure † Maximum tolerated dose (MTD) of CV8102 among the dose groups 50 ug, 100 ug and 250 ug.
Condition † Rabies
Intervention † BiologicalCV8102
Study Arms / Comparison Groups CV8102 Rabipur CV8102 + Rabipur
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Biological
Estimated Enrollment † 72
Start Date † September 2014
Completion Date March 2016
Primary Completion Date February 2016
Eligibility Criteria † Inclusion Criteria: 1. Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial 2. Physical examination and laboratory results without clinically significant findings 3. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 4. Subjects must use reliable forms of contraception (barrier method with spermicidal agent or true abstinence) and must refrain from sperm donation during treatment and the 4-week F/U period after the last treatment. Exclusion Criteria: 1. Use of any investigational or non-registered product (adjuvant, drug) other than CV8102 within 4 weeks preceding the administration of the CV8102, or planned use of any such agent during the trial period 2. Subject has received any licensed or non-licensed vaccines within 4 weeks prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine or planned vaccinations during the trial period 3. Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine. The use of inhaled and nasal steroids, as well as topical steroids outside the vaccination area, will be permitted 4. Any medically diagnosed or suspected immune deficient condition based on medical history and physical examination 5. History of autoimmune disease or suspected autoimmune disease based on medical history and physical examination that cannot be ruled out based on further examinations 6. Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of CV8102 or licensed rabies vaccine 7. Acute disease at the time of enrolment. Acute disease is defined as the presence of any acute condition including but not limited to non-febrile or febrile common colds, urinary tract infections, inflammatory, allergic or traumatic conditions that may interfere with safety assessment of the investigational products 8. Presence or evidence of significant acute or chronic disease, in particular heart disease including coronary artery disease and chronic pulmonary diseases (e.g., chronic obstructive pulmonary disease [COPD]); uncontrolled medical or psychiatric illness (subjects with uncomplicated chronic diagnoses stable and treated for ≥ 3 months e.g., mild hypertension well-controlled with medication, may be enrolled - provided the condition and its therapy are known not to be associated with an immunocompromised state or an autoimmune disease) 9. Major congenital defects 10. Known allergy to any component (or closely related substance) of the licensed rabies vaccine product 11. Known type I allergy to beta-lactam antibiotics 12. Evidence of current alcohol or drug abuse 13. History of any neurological disorders or seizures 14. Known seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (except in subjects previously vaccinated against HBV) or hepatitis C virus (HCV) 15. Foreseeable non-compliance with protocol as judged by the Investigator 16. History of any life-threatening anaphylactic reactions 17. Subjects with impaired coagulation in whom an IM injection is contraindicated. Additional exclusion criteria for subjects participating in the (adjuvanted) rabies vaccination part: 18. Subject has previously received any investigational or licensed rabies vaccine 19. Intending to travel to regions/countries for which rabies vaccinations are recommended or where high risk of infection exists according to travel recommendations by the German Society of Tropical Medicine and International Health (DTG) during the trial and F/U period 20. Subject is taking chloroquine for malaria treatment or prophylaxis.
Gender Male
Ages 18 Years - 40 Years
Accepts Healthy Volunteers Accepts Healthy Volunteers
Contacts †† Angelika Daehling, +49 (0) 69 - 7680 587,
Location Countries † Germany
Administrative Information
NCT ID † NCT02238756
Organization ID CV-8102-201
Secondary IDs †† 2013-004514-18
Responsible Party Sponsor
Study Sponsor † CureVac GmbH
Collaborators ††
Investigators † Principal Investigator: Ingo Meyer, MD, CRS Clinical Research Services Mönchengladbach GmbH
Information Provided By
Verification Date September 2014
First Received Date † September 4, 2014
Last Updated Date September 12, 2014
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
Free Newsletter